Possible therapeutic applications of cannabis in the neuropsychopharmacology field.

Authors: Javier Fernández-Ruiz, Ismael Galve-Roperh, Onintza Sagredo, Manuel Guzmán
European Neuropsychopharmacology, 10 February 2020

Cannabis use induces a plethora of actions on the CNS via its active chemical ingredients, the so-called phytocannabinoids. These compounds have been frequently associated with the intoxicating properties of cannabis preparations. However, not all phytocannabinoids are psychot…

Cannabinoids in depressive disorders.

Authors: Ewa Poleszak, Sylwia Wośko, Karolina Sławińska, Aleksandra Szopa, Andrzej Wróbel, Anna Serefko
Life Sciences, 15 November 2018

Cannabis sativa is one of the most popular recreational and medicinal plants. Benefits from use of cannabinoid agents in epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and others have been suggested. It seems that the endocannabinoid system is also inv…

Marijuana use during and after pregnancy and association of prenatal use on birth outcomes: A population-based study.

Authors: Jean Y. Ko, Van T. Tong, Jennifer M. Bombard, Donald K. Hayes, John Davy, et al
Drug and Alcohol Dependence, June 2018

BACKGROUND: We sought to describe the correlates of marijuana use during and after pregnancy, and to examine the independent relationship between prenatal marijuana use and infant outcomes. STUDY DESIGN: We used state-specific data from the Pregnancy Risk Assessment Monitoring…

Effects of Marijuana on Mental Health: Depression.

Authors: Susan A. Stoner
Alcohol & Drug Abuse Institute, University of Washington, June 2017

THC and CBD appear to have antidepressant-like effects in animal models at certain doses but not others. Marijuana has been associated with diminished motivation, but a distinct “cannabis amotivational syndrome” has yet to be substantiated. Studies looking at whether marijuana…

Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors: Louise Arseneault, Mary Cannon, Richie Poulton, Robin Murray, Avshalom Caspi, Terrie E Moffitt
BMJ, 23 November 2002

The strongest evidence that cannabis use may be a risk factor for later psychosis comes from a Swedish cohort study which found that heavy cannabis use at age 18 increased the risk of later schizophrenia sixfold. This study could not establish whether adolescent cannabis use w…